查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
欧洲微生物组治疗市场预测至 2030 年 - 区域分析 - 按类型、应用程式和最终用户
市场调查报告书
商品编码
1494523

欧洲微生物组治疗市场预测至 2030 年 - 区域分析 - 按类型、应用程式和最终用户

Europe Microbiome Therapeutics Market Forecast to 2030 - Regional Analysis - by Type, Application, and End User
出版日期: | 出版商: The Insight Partners | 英文 71 Pages | 订单完成后即时交付

价格

2022年欧洲微生物组治疗市场价值为9,774万美元，预计到2030年将达到2.1252亿美元；预计2022年至2030年复合年增长率为10.2%。

改善微生物组发现管道的资金流入推动欧洲微生物组治疗市场

研究表明，微生物群的不平衡或破坏可能导致多种疾病，例如发炎性肠道疾病和肥胖，以及精神健康障碍。微生物组在整体健康中的作用的认识引起了人们对开发针对和调节微生物组的疗法的浓厚兴趣。此外，技术和研究工具的进步使得研究和操纵微生物组变得更加容易。新一代定序和宏基因组分析使人们能够更深入地了解微生物群落及其功能。知识的增加为开发标靶疗法开启了新的可能性。例如，2023 年 3 月，德国微生物组生物技术公司 mbiomics GmbH 开发了第一代有效的基于微生物组的疗法。它从 MIG Capital 获得了 1300 万美元（1500 万美元）的融资。这笔资金将用于建立该平台，这将加速第一批候选药物的识别，并加快临床验证的研究工作。随着强有力的临床证据的出现，投资人开始注意到微生物组调节剂公司。增加的资金为公司提供了必要的资源，以克服与高开发和生产成本相关的挑战，最终推动该领域向前发展。

欧洲微生物组治疗市场概述

德国的微生物组治疗研究公司致力于呼吁其他公司投资其研究活动，以提高微生物组产品开发研究的品质。 2023 年 3 月，专注于微生物组的德国生技公司 mbiomics GmbH 在 MIG Capital 领投的 A 轮融资中获得约 1,500 万美元（1,300 万美元）。 mbiomics 利用所得收益建立了策略合作伙伴关係，显着扩大了其在德国的慕尼黑实验室设施和研发团队。在一些 FMT 程序中，传染源可能会从捐赠者转移到患者身上，从而影响结果。因此，德国对微生物组或 FMT 程序的使用制定了特殊规定。在德国，FMT 药物作为药品进行监管；然而，只有当其他治疗方法对艰难梭菌感染和肠道感染等病症无效时，才能使用该产品。因此，儘管微生物组治疗研究的投资激增，但有关这些治疗产品使用的法规可能会阻碍德国欧洲微生物组治疗市场的成长。

欧洲微生物组治疗市场收入及 2030 年预测（百万美元）

欧洲微生物组治疗市场细分

欧洲微生物组治疗市场根据类型、应用、最终用户和国家进行细分。

根据类型，欧洲微生物组治疗市场分为治疗方法和手术方法。到 2022 年，手术细分市场将占据更大份额。

根据应用，欧洲微生物组治疗市场分为代谢紊乱和肥胖、艰难梭菌感染、发炎性肠道疾病等。 2022 年，代谢紊乱和肥胖细分市场占最大份额。

从最终用户来看，欧洲微生物组治疗市场包括医院和诊所、门诊手术中心、家庭护理等。 2022 年，医院和诊所领域占最大份额。

根据国家/地区，欧洲微生物组治疗市场分为英国、德国、法国、义大利、西班牙和欧洲其他地区。 2022 年，德国在欧洲微生物组治疗市场占据主导地位。

Caelus Health BV、Enterome SA、Ferring Holdings SA、Vedanta Biosciences Inc 和 YSOPIA Bioscience SA 是欧洲微生物组治疗市场上的一些领先公司。

目录

第 1 章：简介

第 2 章：执行摘要

  • 重要见解

第 3 章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：欧洲微生物组治疗市场格局

  • 概述
  • 欧洲PEST分析

第 5 章：欧洲微生物组治疗市场 - 主要产业动态

  • 欧洲微生物组治疗市场 - 主要产业动态
  • 主要市场驱动因素
    • 肠道微生物群在维持人类健康的潜力
    • 资金流入改善微生物组发现管道
  • 主要市场限制
    • 开发和生产成本高
  • 主要市场机会
    • 加强研发以更了解人类微生物组
  • 未来主要趋势
    • 人类微生物组治疗的技术进步
  • 驱动因素和限制的影响：

第 6 章：微生物组治疗市场 - 欧洲市场分析

第 7 章：欧洲微生物组治疗市场分析 - 类型

  • 疗法
    • 概述
    • 治疗市场、收入与 2030 年预测
  • 程式
    • 概述
    • 程序市场、收入和 2030 年预测

第 8 章：欧洲微生物组治疗市场分析 - 应用

  • 代谢紊乱与肥胖
    • 概述
    • 代谢紊乱和肥胖市场、收入和 2030 年预测
  • C. 艰难梭菌感染 (CDI)
    • 概述
    • C. 艰难梭菌感染 (CDI) 市场、收入和 2030 年预测
  • 发炎性肠道疾病
    • 概述
    • 发炎性肠道疾病市场、收入和 2030 年预测
  • 其他的
    • 概述
    • 其他市场、收入和 2030 年预测

第 9 章：欧洲微生物组治疗市场分析 - 最终用户

  • 医院和诊所
    • 概述
    • 医院和诊所市场、收入和 2030 年预测
  • 门诊手术中心
    • 概述
    • 门诊手术中心市场、收入与 2030 年预测
  • 居家护理
    • 概述
    • 家庭护理市场、收入和 2030 年预测
  • 其他的
    • 概述
    • 其他市场、收入和 2030 年预测

第 10 章：欧洲微生物组治疗市场 - 国家分析

    • 英国
      • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区

第 11 章：产业格局

  • 概述
  • 欧洲微生物组治疗市场的成长策略

第 12 章：公司简介

  • YSOPIA Bioscience SA
  • Ferring Holdings SA
  • Enterome SA
  • Caelus Health BV
  • Vedanta Biosciences Inc

第 13 章：附录

Product Code: BMIRE00029955

The Europe microbiome therapeutics market was valued at US$ 97.74 million in 2022 and is expected to reach US$ 212.52 million by 2030; it is estimated to record a CAGR of 10.2% from 2022 to 2030.

Inflow of Funds to Ameliorate Microbiome Discovery Pipeline Drives Europe Microbiome Therapeutics Market

Research has shown that imbalances or disruptions in the microbiome can contribute to various conditions, such as inflammatory bowel disease and obesity, as well as mental health disorders. The recognition of the microbiome's role in overall health has generated significant interest in developing therapeutics to target and modulate the microbiome. Additionally, advancements in technology and research tools have made it easier to study and manipulate the microbiome. Next-generation sequencing and metagenomic analysis have allowed for a deeper understanding of microbial communities and their functions. The increased knowledge has opened up new possibilities for developing targeted therapies. For instance, in March 2023, mbiomics GmbH, a German microbiome biotech company, developed the first generation of effective microbiome-based therapeutics. It received a funding of 13 million (US$ 15 million) from MIG Capital. The funding will allow to build the platform, which will accelerate the identification of first-lead drug candidates and speed up research efforts toward clinical validation. As strong clinical evidence becomes available, investors are beginning to take notice of microbiome modulator firms. The heightened funding provides companies with necessary resources to overcome the challenges associated with the high cost of development and production, ultimately driving the field forward.

Europe Microbiome Therapeutics Market Overview

Microbiome therapeutic research companies in Germany are focused on calling other companies to invest in their research activities to improve the quality of research being conducted for microbiome product development. In March 2023, mbiomics GmbH, a German biotech company focused on the microbiome, received ~US$ 15 million (13 million) in a series A financing round led by MIG Capital. mbiomics used the proceeds to embark on strategic partnerships, significantly expanding their Munich laboratory facilities and R&D teams in Germany. In some FMT procedures, infectious agents may be transferred from donor to patient, which affects the outcomes. Hence, Germany has set particular regulations for the use of microbiome or FMT procedures. In Germany, FMT drugs are regulated as a medicinal product; however, the use of this product can be done only when no other treatment is working on conditions such as C. difficile infections and gut infections. Hence, despite an upsurge in investments in research on microbiome therapeutics, regulations regarding the use of these therapeutic products may hamper the growth of the Europe microbiome therapeutics market in Germany.

Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

Europe Microbiome Therapeutics Market Segmentation

The Europe microbiome therapeutics market is segmented based on type, application, end user, and country.

Based on type, the Europe microbiome therapeutics market is bifurcated into therapeutics and procedure. The procedure segment held a larger share in 2022. The therapeutics segment is further subsegmented into fecal microbiota transplantation (FMT), prebiotics & probiotics, and others.

By application, the Europe microbiome therapeutics market is segmented into metabolic disorder and obesity, C. difficile infection, inflammatory bowel disease, and others. The metabolic disorder and obesity segment held the largest share in 2022.

By end user, the Europe microbiome therapeutics market is hospitals and clinics, ambulatory surgical centers, homecare, and others. The hospitals and clinics segment held the largest share in 2022.

Based on country, the Europe microbiome therapeutics market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe microbiome therapeutics market in 2022.

Caelus Health BV, Enterome SA, Ferring Holdings SA, Vedanta Biosciences Inc, and YSOPIA Bioscience SA are some of the leading companies operating in the Europe microbiome therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Microbiome Therapeutics Market Landscape

  • 4.1 Overview
  • 4.2 Europe PEST Analysis

5. Europe Microbiome Therapeutics Market - Key Industry Dynamics

  • 5.1 Europe Microbiome Therapeutics Market - Key Industry Dynamics
  • 5.2 Key Market Drivers
    • 5.2.1 Potential of Gut Microbiota in Maintaining Human Health
    • 5.2.2 Inflow of Funds to Ameliorate Microbiome Discovery Pipeline
  • 5.3 Key Market Restraints
    • 5.3.1 High Cost of Development and Production
  • 5.4 Key Market Opportunities
    • 5.4.1 Increasing R&D to Gain Better Understanding of Human Microbiome
  • 5.5 Key Future Trends
    • 5.5.1 Technological Advancement in Human Microbiome Therapeutics
  • 5.6 Impact of Drivers and Restraints:

6. Microbiome Therapeutics Market - Europe Market Analysis

7. Europe Microbiome Therapeutics Market Analysis - Type

  • 7.1 Therapeutics
    • 7.1.1 Overview
    • 7.1.2 Therapeutics Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 7.2 Procedure
    • 7.2.1 Overview
    • 7.2.2 Procedure Market, Revenue and Forecast to 2030 (US$ Thousand)

8. Europe Microbiome Therapeutics Market Analysis - Application

  • 8.1 Metabolic Disorder and Obesity
    • 8.1.1 Overview
    • 8.1.2 Metabolic Disorder and Obesity Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 8.2 C. Difficile Infection (CDI)
    • 8.2.1 Overview
    • 8.2.2 C. Difficile Infection (CDI) Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 8.3 Inflammatory Bowel Disease
    • 8.3.1 Overview
    • 8.3.2 Inflammatory Bowel Disease Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 8.4 Others
    • 8.4.1 Overview
    • 8.4.2 Others Market, Revenue and Forecast to 2030 (US$ Thousand)

9. Europe Microbiome Therapeutics Market Analysis - End User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Overview
    • 9.1.2 Hospitals and Clinics Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 9.2 Ambulatory Surgical Centers
    • 9.2.1 Overview
    • 9.2.2 Ambulatory Surgical Centers Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 9.3 Homecare
    • 9.3.1 Overview
    • 9.3.2 Homecare Market, Revenue and Forecast to 2030 (US$ Thousand)
  • 9.4 Others
    • 9.4.1 Overview
    • 9.4.2 Others Market, Revenue and Forecast to 2030 (US$ Thousand)

10. Europe Microbiome Therapeutics Market - Country Analysis

  • 10.1. Europe Microbiome Therapeutics Market Revenue and Forecasts and Analysis - By Country
    • 10.1.1 Europe Microbiome Therapeutics Market Revenue and Forecasts and Analysis - By Country
    • 10.1.2 UK
      • 10.1.2.1 UK: Europe Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
      • 10.1.2.2 United Kingdom Europe Microbiome Therapeutics Market Breakdown by Type
        • 10.1.2.2.1 UK: Europe Microbiome Therapeutics Market Breakdown by Therapeutics
      • 10.1.2.3 UK: Europe Microbiome Therapeutics Market Breakdown by Application
      • 10.1.2.4 UK: Europe Microbiome Therapeutics Market Breakdown by End User
    • 10.1.3 Germany
      • 10.1.3.1 Germany: Europe Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
      • 10.1.3.2 Germany: Europe Microbiome Therapeutics Market Breakdown by Type
        • 10.1.3.2.1 Germany: Europe Microbiome Therapeutics Market Breakdown by Therapeutics
      • 10.1.3.3 Germany: Europe Microbiome Therapeutics Market Breakdown by Application
      • 10.1.3.4 Germany: Europe Microbiome Therapeutics Market Breakdown by End User
    • 10.1.4 France
      • 10.1.4.1 France: Europe Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
      • 10.1.4.2 France: Europe Microbiome Therapeutics Market Breakdown by Type
        • 10.1.4.2.1 France: Europe Microbiome Therapeutics Market Breakdown by Therapeutics
      • 10.1.4.3 France: Europe Microbiome Therapeutics Market Breakdown by Application
      • 10.1.4.4 France: Europe Microbiome Therapeutics Market Breakdown by End User
    • 10.1.5 Italy
      • 10.1.5.1 Italy: Europe Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
      • 10.1.5.2 Italy: Europe Microbiome Therapeutics Market Breakdown by Type
        • 10.1.5.2.1 Italy: Europe Microbiome Therapeutics Market Breakdown by Therapeutics
      • 10.1.5.3 Italy: Europe Microbiome Therapeutics Market Breakdown by Application
      • 10.1.5.4 Italy: Europe Microbiome Therapeutics Market Breakdown by End User
    • 10.1.6 Spain
      • 10.1.6.1 Spain: Europe Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
      • 10.1.6.2 Spain: Europe Microbiome Therapeutics Market Breakdown by Type
        • 10.1.6.2.1 Spain: Europe Microbiome Therapeutics Market Breakdown by Therapeutics
      • 10.1.6.3 Spain: Europe Microbiome Therapeutics Market Breakdown by Application
      • 10.1.6.4 Spain: Europe Microbiome Therapeutics Market Breakdown by End User
    • 10.1.7 Rest of Europe
      • 10.1.7.1 Rest of Europe: Europe Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
      • 10.1.7.2 Rest of Europe: Europe Microbiome Therapeutics Market Breakdown by Type
        • 10.1.7.2.1 Rest of Europe: Europe Microbiome Therapeutics Market Breakdown by Therapeutics
      • 10.1.7.3 Rest of Europe: Europe Microbiome Therapeutics Market Breakdown by Application
      • 10.1.7.4 Rest of Europe: Europe Microbiome Therapeutics Market Breakdown by End User

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in Europe Microbiome Therapeutics Market

12. Company Profiles

  • 12.1 YSOPIA Bioscience SA
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Ferring Holdings SA
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Enterome SA
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Caelus Health BV
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Vedanta Biosciences Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. Europe Microbiome Therapeutics Market Segmentation
  • Table 2. Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousand) - Type
  • Table 3. Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousand) - Therapeutics
  • Table 4. Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousand) - Application
  • Table 5. Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousand) - End User
  • Table 6. Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Country
  • Table 7. UK: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
  • Table 8. UK: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
  • Table 9. UK: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
  • Table 10. UK: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
  • Table 11. Germany: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
  • Table 12. Germany: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
  • Table 13. Germany: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
  • Table 14. Germany: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
  • Table 15. France: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
  • Table 16. France: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
  • Table 17. France: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
  • Table 18. France: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
  • Table 19. Italy: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
  • Table 20. Italy: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
  • Table 21. Italy: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
  • Table 22. Italy: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
  • Table 23. ADULT OBESITY, 2030
  • Table 24. CHILD OBESITY, 2030
  • Table 25. Spain: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
  • Table 26. Spain: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
  • Table 27. Spain: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
  • Table 28. Spain: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
  • Table 29. Rest of Europe: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Type
  • Table 30. Rest of Europe: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Therapeutics
  • Table 31. Rest of Europe: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By Application
  • Table 32. Rest of Europe: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands) - By End User
  • Table 33. Recent Growth Strategies in Europe Microbiome Therapeutics Market
  • Table 34. Glossary of Terms, Europe Microbiome Therapeutics Market

List Of Figures

  • Figure 1. Europe Microbiome Therapeutics Market Segmentation, By Country
  • Figure 2. Europe PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Europe Microbiome Therapeutics Market Revenue (US$ Thousand), 2022 - 2030
  • Figure 5. Europe Microbiome Therapeutics Market Share (%) - Type, 2022 and 2030
  • Figure 6. Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousand)
  • Figure 7. Procedure Market Revenue and Forecasts To 2030 (US$ Thousand)
  • Figure 8. Europe Microbiome Therapeutics Market Share (%) - Application, 2022 and 2030
  • Figure 9. Metabolic Disorder and Obesity Market Revenue and Forecasts To 2030 (US$ Thousand)
  • Figure 10. C. Difficile Infection (CDI) Market Revenue and Forecasts To 2030 (US$ Thousand)
  • Figure 11. Inflammatory Bowel Disease Market Revenue and Forecasts To 2030 (US$ Thousand)
  • Figure 12. Others Market Revenue and Forecasts To 2030 (US$ Thousand)
  • Figure 13. Europe Microbiome Therapeutics Market Share (%) - End User, 2022 and 2030
  • Figure 14. Hospitals and Clinics Market Revenue and Forecasts To 2030 (US$ Thousand)
  • Figure 15. Ambulatory Surgical Centers Market Revenue and Forecasts To 2030 (US$ Thousand)
  • Figure 16. Homecare Market Revenue and Forecasts To 2030 (US$ Thousand)
  • Figure 17. Others Market Revenue and Forecasts To 2030 (US$ Thousand)
  • Figure 18. Europe Microbiome Therapeutics Market Breakdown by Key Countries - Revenue (2022) (US$ Thousand)
  • Figure 19. Europe Microbiome Therapeutics Market Breakdown by Key Countries, 2022 and 2030 (%)
  • Figure 20. UK: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)
  • Figure 21. Germany: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)
  • Figure 22. France: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)
  • Figure 23. Italy: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)
  • Figure 24. Spain: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)
  • Figure 25. Rest of Europe: Europe Microbiome Therapeutics Market Revenue and Forecasts To 2030 (US$ Thousands)